Gilbert Tang, MD, surgical director of the structural heart program at the Mount Sinai Health System, discussed a key challenge care teams often encounter during tricuspid valve procedures. 

Gilbert Tang, MD, spoke to Cardiovascular Business about late-breaking data from the TRILUMINATE IDE trial. While early results were promising, these latest findings highlight the TriClip device's true value for the first time.

Six multispecialty cardiovascular societies have called on CMS to approve Medicare payments for tricuspid transcatheter edge-to-edge repair (T-TEER).

Harlan Krumholz, MD, editor-in-chief of the Journal of the American College of Cardiology, said tricuspid valve treatments are a popular topic among cardiologists right now. TAVR research, meanwhile, remains as important as ever.

New late-breaking data presented at TCT confirmed that the first FDA-approved TTVR system for TR is associated with a much better quality of life than medical therapy alone after one year.

CMS is now accepting public comments on this topic until Nov. 2. A final decision is expected by July 2025.

Treatment with TriClip has been consistently associated with minimal adverse events and significant improvements in quality of life. This latest update represents data from nearly 100 patients three years after implantation.  

Patients presenting for TAVR or M-TEER with baseline moderate or severe tricuspid regurgitation were associated with lower post-treatment KCCQ scores and a higher mortality rate. Perhaps treating more of these patients with tricuspid valve repair or replacement could make a difference, researchers noted.